Bezafibrate/chenodeoxycholic acid - Giaconda

Drug Profile

Bezafibrate/chenodeoxycholic acid - Giaconda

Alternative Names: Hepaconda

Latest Information Update: 15 Jun 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Giaconda
  • Class Antivirals; Cholic acids; Fibric acid derivatives
  • Mechanism of Action Cholesterol 7 alpha hydroxylase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 08 Jul 2008 Suspended - Phase-II for Hepatitis C in Australia (PO) for further formulation of Hepaconda® and to secure further funding
  • 25 Jun 2007 Phase-II clinical trials in Hepatitis C treatment in Australia (PO)
  • 09 Mar 2006 Preclinical trials in Hepatitis C treatment in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top